Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...

Merck (MRK) and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that Merck has entered into an exclusive ...

Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...

MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected ...

MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

The deal allows Merck to take over development of privately held LaNova Medicines' LM-299, the companies said on Thursday.

Merck on Thursday said it has secured an exclusive global license to develop, manufacture and commercialize LM-299, an investigational PD-1/VEGF bispecific antibody from Shanghai-based LaNova that is ...